Rep. C. Scott Franklin Sells Johnson & Johnson (NYSE:JNJ) Stock

Representative C. Scott Franklin (R-Florida) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on July 14th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on June 16th. The trade occurred in the Representative's "FIDELITY JOINT TBE" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Visa NYSE: V on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 6/16/2025.
• Sold $15,001 - $50,000 in shares of McDonald's NYSE: MCD on 6/16/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Walmart NYSE: WMT on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Berkshire Hathaway NYSE: BRK.B on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 6/16/2025.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $3.54 during mid-day trading on Tuesday, reaching $167.90. 9,277,637 shares of the company were exchanged, compared to its average volume of 8,151,378. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a fifty day moving average of $154.29 and a 200 day moving average of $155.12. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market cap of $403.99 billion, a PE ratio of 17.96, a PEG ratio of 2.09 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm's revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $2.82 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of JNJ. Brighton Jones LLC increased its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Proficio Capital Partners LLC increased its stake in Johnson & Johnson by 22.0% in the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock worth $2,885,000 after purchasing an additional 3,594 shares during the period. one8zero8 LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $9,930,000. Finally, Pollock Investment Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $1,040,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on JNJ shares. Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. UBS Group upped their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $172.87.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.